Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study
about
Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma modelNeoadjuvant therapy before surgical treatmentNeoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.The emerging role of neoadjuvant chemotherapy for rectal cancerPhase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.The current state of targeted agents in rectal cancer.Advances and challenges in treatment of locally advanced rectal cancer.Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancerCritical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trialThe status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.Controversies in the multimodality management of locally advanced rectal cancer.Current topics in the multimodality treatment of locally advanced rectal cancer.Beyond Histologic Staging: Emerging Imaging Strategies in Colorectal Cancer with Special Focus on Magnetic Resonance Imaging.Total neoadjuvant therapy for rectal cancer: An emerging option.Progress in rectal cancer treatment.The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis.Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer.Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer.Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial
P2860
Q30383248-2DB2BBD4-0FF1-44A5-86F4-BA75ED793EBFQ33697924-FCD875B6-8DE4-4536-AFBF-6D73C5A7FBBCQ34006430-6D36124C-1B6B-41F2-9D58-08A974A5EE95Q34234935-02FDAD0E-58FE-431C-B01A-06ACE67E0A07Q35128016-7FA07DFB-C699-41B5-8F28-72E857B27422Q35129364-128FC82A-BA7A-4619-9B85-BD27DD3285A2Q35475535-F70F44FB-B222-4BA4-9D61-B4840633A417Q35817933-A3143112-045D-4420-A4EE-44553C4C2101Q35920508-D99DA5AC-1185-4A91-92BC-FF3074D2DD0BQ35996651-BC4FC845-F9B9-4361-8BFF-CD26648C25F7Q36025983-E142C8F4-D96F-4292-A635-834960791F31Q36348179-59EB3F1C-0E0C-4907-8C9C-4737A9CBC83EQ36516445-AE389B15-AD6B-4FAB-B730-098A2ED77A77Q36557606-25081EDB-6BCE-48B3-991E-BC25ED8A7ADBQ37015715-39953C73-E841-4E58-8626-7CA87100B1E5Q37038486-3791A08B-194A-44D1-8F0E-1917C29C3145Q38216007-D1562F86-7F80-48ED-B70D-A50FBD86D8E3Q38425364-76B8F640-82E5-4E66-81C5-9BD29AFCAF54Q38691264-DF0FD6E9-ECD9-44E6-9E69-B114E5FC7B42Q38734893-92EBCE4E-C1C7-4626-B3DB-E6BE3DE0B802Q38943223-30405697-8983-43A8-B4AA-E481DBC65119Q39179402-9B9D69C4-3A81-4E25-B709-D089A8C310BFQ39554319-5314CEDB-8613-4F02-B100-CB2FD59A7A31Q49718931-76797E7D-66B7-4F4A-B20E-B3AA5301D74BQ51759783-9A83CB14-BDD6-4EBB-ABEB-C79AF403EAB4Q52642667-4C94B6D4-2033-413F-8B76-B8549B1E9A4EQ53236494-43B6E5D0-A0E1-496F-9F62-4A941C8E2490Q58751227-DDB9AC0A-7F2F-4503-9FF0-0A442FBAB8DC
P2860
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@ast
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@en
type
label
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@ast
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@en
prefLabel
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@ast
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@en
P2093
P2860
P1433
P1476
Addition of bevacizumab to XEL ...... tal cancer: the AVACROSS study
@en
P2093
AVACROSS Study Group
Antonio Arriví
Ferran Losa
Inmaculada Guasch
Isabel Moreno
José María Roca
José Ponce
María José Safont
Miguel Nogué
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0285
P577
2011-04-05T00:00:00Z